Understanding Keratoconus and the Benefits of iLink Corneal Cross-Linking
What Is Keratoconus and How Does It Affect Vision
Keratoconus is a progressive eye condition that causes the cornea to thin and bulge into a cone-like shape, gradually distorting vision and making everyday tasks more difficult. In a healthy eye, the cornea maintains a smooth, dome-like curvature that focuses light precisely onto the retina. With keratoconus, the collagen fibers that provide the cornea's structural integrity begin to weaken, causing the tissue to thin and push outward into an irregular cone shape. According to the National Keratoconus Foundation and peer-reviewed studies, keratoconus affects approximately 1 in 2,000 people in the general population, and with improved corneal imaging technology, early cases are now detected more frequently.
Keratoconus symptoms often develop gradually and may initially resemble ordinary refractive errors. Patients commonly experience increasing nearsightedness or astigmatism that changes frequently, blurred or distorted vision that glasses no longer fully correct, sensitivity to light and glare especially while driving at night, halos or streaking around lights, and frequent changes in eyeglass or contact lens prescriptions.
Keratoconus most commonly appears during the teenage years or early twenties and may continue to progress into the mid-thirties or beyond. A family history of the condition, chronic eye rubbing, and certain connective tissue disorders can increase the likelihood of developing keratoconus. People with allergies or atopic conditions may also be at higher risk, as habitual eye rubbing can accelerate corneal thinning.
How Keratoconus Is Detected Early
Corneal cross-linking outcomes depend heavily on early diagnosis, which is why corneal topography and tomography play such an important role. Topography creates a detailed color-coded map of the cornea's surface curvature, revealing irregular steepening patterns that may indicate early keratoconus. Tomography goes further by measuring the full thickness of the cornea from front to back, detecting thinning that may not be visible on the surface alone.
An eye care provider may suspect keratoconus when a patient's prescription changes frequently, when standard glasses or soft contact lenses no longer provide clear vision, or when topography reveals irregular astigmatism. A scissors-reflex during retinoscopy and a history of vigorous eye rubbing are additional clinical signs that warrant more detailed evaluation.
Because keratoconus is a progressive condition, patients who are diagnosed early benefit from regular monitoring to track changes in corneal shape and thickness over time. Serial topography measurements taken across several visits help determine whether the condition is stable or advancing. This ongoing monitoring is essential for deciding when intervention should be recommended.
What Is iLink Corneal Cross-Linking
iLink is the first and only FDA-approved corneal cross-linking procedure, designed to strengthen a weakened cornea and slow or halt the progression of keratoconus. The iLink procedure combines riboflavin (vitamin B2) eye drops with controlled ultraviolet A light to create new bonds, called cross-links, between collagen fibers within the cornea. This process stiffens and reinforces the corneal tissue. The procedure is performed as a same-day outpatient treatment and typically takes about 60 to 90 minutes to complete.
Riboflavin serves as a photosensitizer, meaning it absorbs the UV light and triggers a chemical reaction within the corneal tissue. During the iLink procedure, Photrexa Viscous and Photrexa eye drops are applied to the cornea, where they saturate the stromal layer. Once the cornea is sufficiently saturated, UVA light from the KXL system is directed at the eye for approximately 30 minutes, activating the riboflavin and generating the new collagen cross-links that strengthen the cornea.
While some providers may offer alternative cross-linking techniques, iLink is the only procedure that has undergone rigorous FDA clinical trials and received approval for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Choosing an FDA-approved procedure gives patients the assurance of established safety and efficacy data.
How iLink Stops Keratoconus Progression
Keratoconus develops in part because the natural collagen cross-links within the cornea are insufficient to maintain normal shape and rigidity. The iLink procedure creates new chemical bonds between adjacent collagen fibers, significantly increasing the biomechanical strength of the corneal tissue. Research has shown that cross-linking can increase corneal stiffness substantially, helping the tissue resist the forces that cause progressive bulging and thinning.
Once the new collagen bonds are established, the cornea is better able to maintain its current curvature rather than continuing to steepen and thin. Clinical studies have demonstrated that over 90 percent of treated eyes show stabilization of corneal shape after cross-linking. In some patients, mild flattening of the cone may occur over the months following treatment.
Before cross-linking became available, many keratoconus patients eventually required a corneal transplant when their vision could no longer be adequately corrected with glasses or contact lenses. By intervening early with iLink, the goal is to stabilize the cornea well before it reaches the advanced stages where transplant surgery becomes necessary.
Frequently Asked Questions
iLink is FDA-approved for patients aged 14 and older with documented progressive keratoconus or corneal ectasia following refractive surgery. Candidates typically show measurable changes in corneal shape on serial topography over time. Our cornea specialists evaluate your imaging results, corneal thickness, and rate of progression to determine whether cross-linking is appropriate.
The procedure begins with numbing drops to keep you comfortable. The outer layer of the cornea, called the epithelium, is gently removed to allow the riboflavin drops to penetrate the corneal tissue more effectively. Riboflavin drops are then applied over a period of roughly 30 minutes, followed by approximately 30 minutes of controlled UV light exposure. A bandage contact lens is placed on the eye afterward to protect the surface as it heals.
Most patients experience some discomfort, light sensitivity, and tearing during the first few days. The bandage contact lens is typically removed within five to seven days once the epithelium has regenerated. Vision may remain blurry for several weeks, and it can take one to three months for vision to begin stabilizing.
Clinical trials supporting the FDA approval of iLink demonstrated that the procedure successfully stabilized or improved corneal curvature in the majority of treated eyes. Published studies report a success rate of over 90 percent in halting keratoconus progression. The procedure has been shown to provide long-lasting stabilization, with sustained benefits observed for years following treatment.
Because iLink is the only FDA-approved cross-linking procedure, it is widely covered by major insurance plans. Greater than 95 percent of the commercially insured population has access to coverage for this treatment. We recommend verifying your benefits before scheduling.
What our Patients say
4.8
Reviews
(3547)